72 results on '"Abahssain H"'
Search Results
2. Metastatic Desmoplastic Small Round Cell Tumor Controlled by an Anthracycline-Based Regimen: Review of the Role of Chemotherapy
- Author
-
Mrabti, H., Kaikani, W., Ahbeddou, N., Abahssain, H., El Khannoussi, B., Amrani, M., and Errihani, H.
- Published
- 2012
- Full Text
- View/download PDF
3. Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer
- Author
-
Sow, M.L., primary, El Yacoubi, H., additional, Moukafih, B., additional, Balde, S., additional, Akimana, G., additional, Elkhoyaali, S., additional, Abahssain, H., additional, Mrabti, H., additional, Elghissassi, I., additional, and Errihani, H., additional
- Published
- 2019
- Full Text
- View/download PDF
4. 3PC-038 Ifosfamide-induced encephalopathy: quality control of intravenous solution of methylene blue formulated and prepared in pharmacy using a disposable closed system transfer device – a case report
- Author
-
Benabbes, M, primary, Chentoufi, M Alami, additional, Lakhdissi, A, additional, Abahssain, H, additional, Errihani, H, additional, and Meddah, B, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Targeting Angiogenesis in Thyroid Cancer
- Author
-
Lkhoyaali, S., primary, Benhmida, S., additional, Aitelhaj, M., additional, Layachi, M., additional, Abahssain, H., additional, Ismaili, H.N., additional, and Errihani, H., additional
- Published
- 2015
- Full Text
- View/download PDF
6. Cancer du sein chez la femme âgée de plus de 70ans : expérience de l’Institut national d’oncologie de Rabat
- Author
-
Mohtaram, A., primary, Aaribi, I., additional, Sekkate, S., additional, Sghiri, T., additional, Benameur, M., additional, Abahssain, H., additional, and Errihani, H., additional
- Published
- 2011
- Full Text
- View/download PDF
7. Prise en charge d’un carcinome neuroendocrine des fosses nasales dans un contexte de grossesse
- Author
-
Kairouani, M., primary, Guerrounai, A., additional, Sekkate, S., additional, Abahssain, H., additional, Rahhali, R., additional, El Ghissassi, I., additional, Boutayeb, S., additional, Rzine, A., additional, and Errihani, H., additional
- Published
- 2011
- Full Text
- View/download PDF
8. 5198 POSTER The Impact of Obesity on the Prognosis of Operable Breast Cancer in Morrocan Women
- Author
-
Kairouani, M., primary, Abahssain, H., additional, Sekkate, S., additional, Rahhali, R., additional, Boutayeb, S., additional, Mrabti, H. El, additional, and Errihani, H., additional
- Published
- 2011
- Full Text
- View/download PDF
9. Postoperative adjuvant chemoradiation in gastric carcinoma: Results of a retrospective analysis.
- Author
-
Abahssain, H., primary, Lalya, I., additional, Zakkouri, F. A., additional, Tazi, m. A., additional, Mrabti, H., additional, Kebdani, T., additional, Ichou, M., additional, Benjaafar, N., additional, and Errihani, H., additional
- Published
- 2011
- Full Text
- View/download PDF
10. Smoking, passive smoking, and lung cancer cell types among women in Morocco: Analysis of epidemiologic profiling of 101 cases.
- Author
-
Errihani, H., primary, Ouaouch, S., additional, Abahssain, H., additional, Razine, R., additional, Mrabti, H., additional, Abouqal, R., additional, Ichou, M., additional, Benjaafar, N., additional, and Zakkouri, F. A., additional
- Published
- 2011
- Full Text
- View/download PDF
11. Metastatic Desmoplastic Small Round Cell Tumor Controlled by an Anthracycline-Based Regimen: Review of the Role of Chemotherapy
- Author
-
Mrabti, H., primary, Kaikani, W., additional, Ahbeddou, N., additional, Abahssain, H., additional, El Khannoussi, B., additional, Amrani, M., additional, and Errihani, H., additional
- Published
- 2011
- Full Text
- View/download PDF
12. La place de la radiothérapie dans la prise en charge du cancer du sein chez la femme de moins de 35 ans
- Author
-
Abahssain, H., primary, Lalya, I., additional, Tazi, M.A., additional, M’rabet, F.Z., additional, Ismaili, N., additional, M’rabti, H., additional, Benjaafar, N., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
13. Cas clinique d’adénocarcinome à cellules dissociées de l’ouraque
- Author
-
Abahssain, H., primary, Naciri, S., additional, Mellas, N., additional, M’rabti, H., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
14. À propos d’un cas d’association de mycosis fongoïde et de syndrome néphrotique avec revue de littérature
- Author
-
Kairouani, M., primary, Sekkate, S., additional, Abahssain, H., additional, Moukrim, M., additional, Assebane, A., additional, El M’rabti, H., additional, Guedari, B., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
15. Métastases choroïdiennes révélatrice d’un carcinome vésiculaire de la thyroïde
- Author
-
Kairouani, M., primary, Sekkate, S., additional, Abahssain, H., additional, El M’rabti, H., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
16. À propos d’un cas d’association simultanée de tuberculose ganglionnaire et de carcinome spinocellulaire cutané métastasé
- Author
-
Kairouani, M., primary, Sekkate, S., additional, Abahssain, H., additional, El M’rabti, H., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
17. A propos de deux cas de carcinome mucoépidermoïde osseux avec revue de la littérature
- Author
-
Sekkate, S., primary, Kairouani, M., additional, Abahssain, H., additional, M’rabti, H., additional, Gueddari, B.K., additional, and Errihani, H., additional
- Published
- 2010
- Full Text
- View/download PDF
18. P.188 Controverse dans le traitement des lymphomes non hodgkiniens gastriques primitifs à grandes cellules B localisé
- Author
-
Sbitti, Y., primary, Kadiri, H., additional, Fetohi, M., additional, Berrada, N., additional, Elghissassi, I., additional, M’Rabti, H., additional, Abahssain, H., additional, Boutayeb, S., additional, Ichou, M., additional, and Errihani, H., additional
- Published
- 2009
- Full Text
- View/download PDF
19. Cancer du sein chez la femme âgée de plus de 70 ans : expérience de l’Institut national d’oncologie de Rabat
- Author
-
Mohtaram, A., Aaribi, I., Sekkate, S., Sghiri, T., Benameur, M., Abahssain, H., and Errihani, H.
- Published
- 2011
- Full Text
- View/download PDF
20. A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy
- Author
-
Mouna Kairouani, Sekkate, S., Ismaili, N., Abahssain, H., and Errihani, H.
- Subjects
Adult ,Male ,mycosis fungoide ,Lung Neoplasms ,Skin Neoplasms ,Case Report ,chemotherapy ,Mycosis Fungoides ,Antineoplastic Combined Chemotherapy Protocols ,Edema ,Humans ,Whole Body Imaging ,Cyclophosphamide ,Neoplasm Staging ,lcsh:R5-920 ,nephrotic syndrome ,lcsh:Public aspects of medicine ,lcsh:RA1-1270 ,Intensive Care Units ,Treatment Outcome ,Doxorubicin ,Vincristine ,Prednisone ,Tomography, X-Ray Computed ,lcsh:Medicine (General) ,multidisciplinary - Abstract
The occurrence of the nephrotic syndrome during mycosis fungoide is very unusual. We report a rare case of mycosis fungoide revealed by hydrops related to nephrotic syndrom in a 37-year old male patient. He has been admitted to intensive care unit because of a breathing distress and a hydrophobs. Whole body computed tomography scan revealed bilateral axillary, cervical lymph nodes, tumoral infiltration of the subcutaneous tissue in the cervicothoracic and abdominal regions, multiples bilateral pulmonary metastasis, bilateral pleural effusion, and abdominal effusion; the kidneys were normal. The patient was staged IVb (T3N3M1). He was treated with CHOP (cyclophosphamide, Doxorubicin, Vincristin and prednisone). Evolution after eight cycles of chemotherapy was spectacular. The development of nephrotic syndrom secondary to mycosis fungoide is rare. It requires a multidisciplinary approach with nephrologists and oncologists.
21. Les tumeurs malignes primitives de l’intestin grèle: Aspects cliniques et thérapeutiques de 27 patients
- Author
-
Abahssain Halima, Mokrim Maha, Lalya Issam, M’rabti Hind, and Errihani Hassan
- Subjects
Intestin grèle ,tumeur maligne ,diagnostic ,chirurgie ,chimiothérapie ,survie ,Maroc ,Medicine - Abstract
Les tumeurs malignes de l'intestin grèle (TMPIG) sont des tumeurs rares. Elles représentent 1 à 5% de toutes les tumeurs du tube digestif. Elles sont caractérisées par une hétérogénéité anatomopathologique et une symptomatologie pauvre et non spécifique entrainant ainsi un retard diagnostic, des difficultés Thérapeutiques et donc un mauvais pronostic. Nous rapportant les caractéristiques épidémiologiques, diagnostiques et thérapeutiques ainsi que la survie des patients atteints des TMIG au sein de l’institut national d’oncologie de Rabat. Il s’agit d’une analyse rétrospective des dossiers cliniques des 27 patients ayant le diagnostic de tumeurs malignes de l’intestin grèle admis dans notre institut entre 1998 et 2002. L’âge médian était de 46 ans (15-70 ans). Le délai médian de diagnostic était de 6 mois (0-96 mois). La douleur abdominale était le symptôme le plus fréquent (77.8%). L’étude anatomopathologique a montré 63% de lymphome non Hodgkinie, 14.8% d’adénocarcinome, 7.4% de tumeur stromale, 7.4% de carcinome neuroendocrine et 7.4% de sarcome intestinal. Vingt patients (76. 9%) ont eu une résection chirurgicale et 14 patients (53. 8%) ont eu une chimiothérapie en fonction du stade de la maladie et du type histologique. Après un recul médian de 11.6 mois, la survie globale après 12 mois était de 44.4% et la médiane de survie était de 11.6 mois. Les tumeurs malignes de l’intestin grèle sont rares. Leur diagnostic est tardif limitant ainsi la prise en charge thérapeutique curative. Les cliniciens doivent ètre avertis des symptômes gastro-intestinaux non spécifiques
- Published
- 2011
22. 3PC-038 Ifosfamide-induced encephalopathy: quality control of intravenous solution of methylene blue formulated and prepared in pharmacy using a disposable closed system transfer device – a case report
- Author
-
Benabbes, M, Chentoufi, M Alami, Lakhdissi, A, Abahssain, H, Errihani, H, and Meddah, B
- Abstract
BackgroundEncephalopathy is a rare but serious central nervous system toxicity of ifosfamide. Its clinical symptoms are confusion, stupor, seizures, hallucinations and blurred vision.1The methylene blue (MB) is administered as an antidote to the encephalopathy.PurposeDescription of MB formulation and control quality analysis of the preparation and safety case of encephalopathy associated with ifosfamide in the absence of MB injectable in the pharmaceutical market in the country.Material and methodsInitially the MB solution 10 mg/ml for intravenous administration was prepared. A disposable closed system transfer device with filter 0. 15 µm was used, so as to perform a sterile filtration. Next, an analytical control of drug substance and drug product was carried out in accordance with United States Pharmacopoeia. Finally, the preparation was administrated to the patient.ResultsA 60-year-old woman had a uterine leiomyosarcoma in February 2016. The patient received the first cure of doxorubicin (20 mg/m2), ifosfamide (2.5 g/m2) and mesna (2.5 g/m2). On the third day of treatment, the patient had obnubilation and awareness troubles. Ifosfamide-induced encephalopathy was suspected. A treatment with MB was proposed, but unfortunately the product is not marketed in the country. The MB was prepared at the pharmacy with serum glucose 5%: every 1 ml contains 10 mg of drug substance. It has the same visible absorption spectrum as the MB standard solution, contains less than 2.5 USP endotoxin unit per ml, has an osmolality of 308 mmol/Kg, a pH of 4.76 and the preparation was sterile. The drug substance was identified with infrared absorption, The patient received the MB solution in a dose of 6×50 mg day-1. The encephalopathy was resolved with recovery at the neurological level.ConclusionThe MB continues to be an effective antidote for encephalopathy associated with ifosfamide. As was seen in our patient, a dose of 6×50 mg day-1was sufficient for the management of encephalopathy. Our result is consistent with a previous report.Reference and/or Acknowledgements1. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Brit J Cancer2000;82(2):291–294.No conflict of interest
- Published
- 2018
- Full Text
- View/download PDF
23. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology
- Author
-
Rais Ghizlane, Raissouni Soundouss, Aitelhaj Meryem, Rais Fadoi, Naciri Sara, Khoyaali Siham, Abahssain Halima, Bensouda Youssef, Khannoussi Basma, Mrabti Hind, and Errihani Hassan
- Subjects
Gynecology and obstetrics ,RG1-991 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. This is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. The aim of this study is to determine the clinicopathological, therapeutic features and outcomes associated with this type of breast cancer. Methods This is a retrospective study of confirmed triple negative breast cancer females collected at the National institute of oncology of Rabat in Morocco, between January 2007 and December 2008. Epidemiological, clinical, histological, therapeutic and evolutive data were analyzed. OS and DFS rates were estimated by Kaplan-Meier analysis. Results A total of one 152 patients with breast cancer, were identified as having triple-negative breast cancer (16,5%). The median age at diagnosis was 46 years. 130 patients (86%) had infiltrating ductal carcinoma and thirteen had medullar carcinoma (9%). 84 cases (55%) were grade III Scarff-Bloom-Richardson (SBR). 48 % had positive lymph nodes, and 5 % had distant metastases at diagnosis. According TNM staging, 12 patients (8%) had stage I, 90 patients (60%) had stage II and the 43(28%) had stage III. 145 patients received surgery. 41 (28%) had conservative surgery and 104 (72%) received radical mastectomy with axillary lymph nodes dissection. 14 patients with advanced tumors or inflammatory breast cancer have received neoadjuvant chemotherapy and four patients (28%) had complete pathologic response. From 131 patients how received adjuvant chemotherapy, 99 patients (75,5%) had Anthracycline based chemotherapy) and 27 patients (20,6%) had sequential Anthracycline and docetaxel,. Seven patients with metastatic disease received anthracycline-based regimen in the first line metastatic chemotherapy. The median follow-up time was 46 months (range 6,1 -60 months). Overall survival at 5 years for all patients was 76,5%. Conclusion These results suggest that most TNBC characteristics in Moroccan patients are in accordance with literature data, especially concerning young age at diagnosis high grade tumors, advanced stage at diagnosis, and short time to relapse. Although the high response rate to chemotherapy, the overall prognosis of this subset of tumors remains poor.
- Published
- 2012
- Full Text
- View/download PDF
24. Breast cancer in moroccan young women: a retrospective study
- Author
-
El Mesbahi Omar, M'rabti Hind, Tazi Mohammed, Razine Rachid, Ismaili Nabil, EL M'Rabet Fatima, Lalya Issam, Abahssain Halima, Benjaafar Nourddine, Abouqal Redouane, and Errihani Hassan
- Subjects
Medicine ,Biology (General) ,QH301-705.5 ,Science (General) ,Q1-390 - Abstract
Abstract Background Breast cancer is uncommon in young women and induces more aggressive biologic characteristics. Survival in young women has been widely studied in developed countries. Less favorable prognosis and low survival were found. In Morocco, this study is the first investigation of clinical features, treatment and prognosis associated with breast cancer in young women. Findings Four hundred and nine women aged 35 years or less were included in this study. All these women were diagnosed as having breast cancer at the National Institute of Oncology in Rabat, Morocco between 2003 and 2007. The relation between clinical and therapeutic characteristics and event-free survival (EFS) and overall survival (OS) were assessed by Cox regression analysis. The median age of the patients was 32 years. Fifty three patients (13%) have metastatic disease at diagnosis and 356 patients (87%) had localised disease. In 57.9% of the cases, the estrogen receptors status was positive. The median follow-up was 32.2 months. After 3 years the survival rate was 80.6%. In the case of localised disease, OS and EFS at 3 years were 83.2% and 62.5%, respectively. OS and EFS at 3 years was higher in patients with stage I than patients with stage II and stage III (p = 0.001). Positive estrogen receptors was significantly associated to OS and EFS at 3 years compared to negative estrogen receptors (p = 0.001). Adjuvant chemotherapy, adjuvant radiotherapy and adjuvant hormone therapy were associated with net benefit in OS and EFS at 3 years. Cox regression analysis showed that negative ER was significantly associated with poorer OS (HR = 2.42, 95% CI = 1.25 - 4.66, p < 0.009) and poorer EFS (HR = 1.73, 95%CI = 1.05 - 2.86, p = 0.03). Stage III disease were associated to poorer EFS (HR = 5.35, 95%CI = 1.60 -17.84, p = 0.006). Conclusions In Morocco, young women with breast cancer had less favorable prognosis. Multivariate analysis showed that negative hormone receptor status was associated with lower EFS and OS. Clinical trials should be launched to improve the survival of these young women with breast cancer.
- Published
- 2010
- Full Text
- View/download PDF
25. Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution
- Author
-
El Guddari Brahim, Benjaafar Noureddine, Aassab Rachi, Abahssain Halima, Belbaraka Rhizlane, Boulaamane Lamia, Lalya Issam, Elmajjaoui Sanaa, Ismaili Nabil, El Mesbahi Omar, Sbitti Yassir, Ismaili Mohammed, and Errihani Hassan
- Subjects
Medicine ,Biology (General) ,QH301-705.5 ,Science (General) ,Q1-390 - Abstract
Abstract Background Concurrent chemoradiotherapy (CCRT) after breast surgery was investigated by few authors and remains controversial, because of concerns of toxicity with taxanes/anthracyclines and radiation. This treatment is not standard and is more commonly used for locally advanced breast cancer. The aim of our study was to evaluate the efficacy and safety of the concomitant use of anthracycline with radiotherapy (RT). Findings Four hundred women having operable breast cancer, treated by adjuvant chemotherapy (CT) and RT in concomitant way between January 2001 and December 2003, were included in this retrospective cohort study. The study compares 2 adjuvant treatments using CCRT, the first with anthracycline (group A) and the second with CMF (group B). The CT treatment was repeated every 21 days for 6 courses and the total delivered dose of RT was 50 Gy, divided as 2 Gy daily fractions. Locoregional recurrence free (LRFS), event free (EFS), and overall survivals (OS) were estimated by the Kaplan-Meier method. The log-rank test was used to compare survival events. Multivariate Cox-regression was used to evaluate the relationship between patient characteristics, treatment and survival. In the 2 groups (A+B) (n = 400; 249 in group A and 151 in group B), the median follow-up period was 74.5 months. At 5 years, the isolated LRFS was significantly higher in group A compared to group B (98.7% vs 95.3%; hazard ratio [HR] = 0.258; 95% CI, 0.067 to 0.997; log-rank P = .034). In addition, the use of anthracycline regimens was associated with a higher rate of 5 years EFS (80.4% vs 75.1%; HR = 0.665; 95% CI, 0.455 to 1.016; log-rank P = .057). The 5 years OS was 83.2% and 79.2% in the anthracycline and CMF groups, respectively (HR = 0.708; 95% CI, 0.455 to 1.128; log-rank P = .143). Multivariate analysis confirmed the positive effect of anthracycline regimens on LRFS (HR = 0.347; 95% CI, 0.114 to 1.053; log-rank P = .062), EFS (HR = 0.539; 95% CI, 0.344 to 0.846; P = 0.012), and OS (HR = 0.63; 95% CI, 0.401 to 0.991; P = .046). LRFS, EFS and OS were significantly higher in the anthracycline group where the patients (n = 288) received more than 1 cycle of concurrent CT (P = .038, P = .026 and P = .038, respectively). LRFS and EFS were significantly higher in the anthracycline group within the BCT subgroup (P = .049 and P = .04, respectively). There were more hematologic, and more grade 2/3/4 skin toxicity in the anthracycline group. Conclusions After mastectomy or BCT, the adjuvant treatment based on anthracycline and concurrent RT reduced breast cancer relapse rate, and significantly improved LRFS, EFS and OS in the patients receiving more than 1 cycle of concurrent CT. There were more hematologic and non hematologic toxicities in the anthracycline group.
- Published
- 2010
- Full Text
- View/download PDF
26. Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
- Author
-
Abahssain Halima, Kairouani Mouna, Gherman Robert, M'Rabti Hind, and Errihani Hassan
- Subjects
Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Adult granulosa cell tumor associated with antecedent use of tamoxifen as adjuvant hormonotherapy for breast cancer is rare. The pathogenesis of this occurrence remains difficult to explain. The estrogenic effect of tamoxifen can be one such explanation. Case presentation A 47 year-old women was treated with surgery, chemotherapy, radiotherapy and tamoxifen for stage III estrogen receptor positive breast carcinoma. Ten months after stopping tamoxifen, we diagnosed a stage Ic granulosa cell tumor of the ovary. Conclusions Use of tamoxifen has been found to be associated with gynecological tumors like endometrial carcinoma. Its association with granulosa cell tumor of the ovary is uncommon. Only two previous cases have been reported in literature.
- Published
- 2010
- Full Text
- View/download PDF
27. 128P Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer.
- Author
-
Sow, M L, Yacoubi, H El, Moukafih, B, Balde, S, Akimana, G, Elkhoyaali, S, Abahssain, H, Mrabti, H, Elghissassi, I, and Errihani, H
- Subjects
- *
NON-small-cell lung carcinoma - Published
- 2019
- Full Text
- View/download PDF
28. Impact of clinical breast examination-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco.
- Author
-
Selmouni F, Bendahhou K, Sauvaget C, Abahssain H, Lucas E, Muwonge R, Mimouni H, Ismaili R, Bidar S, Benkaddour FZ, Abousselham L, Chami Khazraji Y, Belakhel L, and Basu P
- Subjects
- Humans, Female, Morocco epidemiology, Middle Aged, Prospective Studies, Adult, Aged, Survival Rate, Critical Pathways, Referral and Consultation statistics & numerical data, Breast Neoplasms mortality, Breast Neoplasms diagnosis, Breast Neoplasms therapy, Breast Neoplasms pathology, Early Detection of Cancer, Neoplasm Staging
- Abstract
Background: This study aimed to indirectly examine whether the implementation of clinical breast examination-based screening program in Morocco has been successful in downstaging and improving survival rates. Breast cancer patients detected through the screening pathway were compared with those detected through self-referral over the same period in terms of cancer stage at diagnosis, tumor characteristics, care delays, and survival., Methods: A prospective observational study was conducted between April 2019 and August 2020 at two major public oncology centers., Results: A total of 896 women with confirmed breast cancer were recruited (483 were program-referred and 413 were self-referred). The authors did not report any significant difference between the two groups in terms of stage at diagnosis, molecular profile, or histopathological grade. Early-stage cancer (stage I-II) was detected in 55.7% of self-referred participants compared to 55.5% of program-referred participants. Median intervals between symptom recognition, pathological diagnosis, and treatment initiation were not significantly different between the two groups. Similarly, survival after treatment showed no significant difference between patients screened by the program and self-referred patients. The 3-year survival rate after treatment was 94.5% for patients referred through the program and 88.6% for patients not referred through the program (p = .16)., Conclusions: This study highlights the importance of equitable and timely access to high-quality diagnosis and treatment facilities, leading to substantial downstaging and enhanced survival rates. Continued efforts to improve quality and expand coverage to include asymptomatic women will consolidate the health infrastructure gains achieved by the Moroccan breast cancer screening program., (© 2024 World Health Organization; licensed by American Cancer Society. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
29. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
- Author
-
Rizzo A, Monteiro FSM, Ürün Y, Massari F, Park SH, Bourlon MT, Poprach A, Rizzo M, Takeshita H, Giannatempo P, Soares A, Roviello G, Molina-Cerrillo J, Carrozza F, Abahssain H, Messina C, Kopp RM, Pichler R, Formisano L, Tural D, Atzori F, Calabrò F, Kanesvaran R, Buti S, and Santoni M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological pharmacology, Urologic Neoplasms drug therapy, Urologic Neoplasms pathology, Aged, 80 and over, Adult, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized pharmacology
- Abstract
Background: The benefit of immune checkpoint inhibitors (ICIs) for poor performance status patients with advanced urothelial carcinoma (UC) remains unknown., Objective: In the present sub-analysis of the ARON-2 study, we investigated the role of pembrolizumab for advanced UC patients with ECOG (Eastern Cooperative Oncology Group) performance status (ECOG-PS) 2., Patients and Methods: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of advanced UC progressing or recurring after platinum-based therapy and treated with pembrolizumab between 1 January 2016 to 1 April 2024 were included. In this sub-analysis we focused on patients with ECOG-PS 2., Results: We included 1,040 patients from the ARON-2 dataset; of these, 167 patients (16%) presented an ECOG-PS 2. The median overall survival (OS) was 14.8 months (95% confidence interval (CI) 12.5-16.1) in the overall study population, 18.2 months (95% CI 15.8-22.2) in patients with ECOG-PS 0-1, and 3.7 months (95% CI 3.2-5.2) in subjects with ECOG-PS 2 (p < 0.001). The median progression-free survival (PFS) in the overall study population was 5.3 months (95% CI 4.3-97.1), 6.2 months (95% CI 5.5-97.1) in patients with ECOG-PS 0-1, and 2.8 months (95% CI 2.1-3.4) in patients with ECOG-PS 2. Among the latter, liver metastases and progressive disease during first-line therapy were significant predictors of OS at both univariate and multivariate analyses. For PFS, univariate and multivariate analyses showed a prognostic role for lung metastases, liver metastases, and progressive disease during first-line therapy., Conclusions: This large real-world evidence study suggests the effectiveness of second-line pembrolizumab for mUC patients with poor performance status. The presence of liver metastases and progressive disease during first-line therapy is associated with worse clinical outcomes and, thus, should be taken into account when making treatment decisions in clinical practice., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
30. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
- Author
-
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, and Santoni M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Aged, 80 and over, Antineoplastic Agents, Immunological therapeutic use, Urologic Neoplasms pathology, Urologic Neoplasms mortality, Urologic Neoplasms therapy, Urologic Neoplasms drug therapy, Radiosurgery methods, Retrospective Studies, Urinary Bladder Neoplasms therapy, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms drug therapy, Adult, Carcinoma, Transitional Cell therapy, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell drug therapy, Treatment Outcome, Combined Modality Therapy, Progression-Free Survival, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage
- Abstract
The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizumab after platinum-based-chemotherapy. Medical records of 837 patients were reviewed from 60 institutions in 20 countries. Two hundred and sixty-two patients (31%) received radiotherapy (cohort A), of whom 193 (23%) received CRT and 69 (8%) received SBRT. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. With a median follow-up of 22.7 months, the median OS was 10.2 months, 6.8 months and 16.0 months in no RT, CRT and SBRT subgroups (p = 0.005), with an 1y-OS rates of 47%, 34% and 61%, respectively (p < 0.001). The 1y-OS rate in the SBRT subgroup were significantly higher for both lower (63%) and upper tract UC (68%), for pure urothelial histology (63%) and variant histologies (58%), and for patients with bone (40%) and lymph-node metastases (61%). Median PFS was 4.8 months, 9.6 months and 5.8 months in the CRT, SBRT and no RT subgroups, respectively (p = 0.060). The 1y-PFS rate was significantly higher (48%) in the SBRT population and was confirmed in all patient subsets. The difference in terms of ORR was in favour of SBRT. Our real-world analysis showed that the use of SBRT/pembrolizumab combination may play a role in a subset of aUC patients to increase disease control and possibly overall survival., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
31. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
- Author
-
Abahssain H, Souadka A, Alem R, Santoni M, Battelli N, Amela E, Lemaire A, Rodriguez J, and Errihani H
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Female, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Triple Negative Breast Neoplasms drug therapy, Capecitabine therapeutic use, Neoadjuvant Therapy methods
- Abstract
Background: Triple-negative breast cancer (TNBC) remains a clinically challenging subtype due to its aggressive nature and limited treatment options post-neoadjuvant failure. Historically, capecitabine has been the cornerstone of adjuvant therapy for TNBC patients not achieving a pathological complete response (pCR). However, the integration of new modalities such as immunotherapy and PARP inhibitors has prompted a re-evaluation of traditional post-neoadjuvant approaches., Methods: This review synthesizes data from pivotal clinical trials and meta-analyses to evaluate the efficacy of emerging therapies in the post-neoadjuvant setting. We focus on the role of immune checkpoint inhibitors (ICIs), PARP inhibitors (PARPis), and antibody-drug conjugates (ADCs) alongside or in place of capecitabine in TNBC treatment paradigms., Results: The addition of ICIs like pembrolizumab to neoadjuvant regimens has shown increased pCR rates and improved event-free survival, posing new questions about optimal post-neoadjuvant therapies. Similarly, PARPis have demonstrated efficacy in BRCA-mutated TNBC populations, with significant improvements in disease-free survival (DFS) and overall survival (OS). Emerging studies on ADCs further complicate the adjuvant landscape, offering potentially efficacious alternatives to capecitabine, especially in patients with residual disease after neoadjuvant therapy., Discussion: The challenge remains to integrate these new treatments into clinical practice effectively, considering factors such as drug resistance, patient-specific characteristics, and socio-economic barriers. This review discusses the implications of these therapies and suggests a future direction focused on personalized medicine approaches in TNBC., Conclusions: As the treatment landscape for TNBC evolves, the role of capecitabine is being critically examined. While it remains a viable option for certain patient groups, the introduction of ICIs, PARPis, and ADCs offers promising alternatives that could redefine adjuvant therapy standards. Ongoing and future trials will be pivotal in determining the optimal therapeutic strategies for TNBC patients with residual disease post-neoadjuvant therapy.
- Published
- 2024
- Full Text
- View/download PDF
32. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
- Author
-
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, Kopp RM, Fiala O, Galli L, Myint ZW, Tural D, Soares A, Pichler R, Mennitto A, Abahssain H, Calabrò F, Monteiro FSM, Albano A, Mollica V, Giudice GC, Takeshita H, and Santoni M
- Abstract
Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6-12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9-6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status., (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2024
- Full Text
- View/download PDF
33. Navigating the complexity of post-NAT therapy in breast cancer: The role of ctDNA testing.
- Author
-
Abahssain H and Souadka A
- Subjects
- Humans, Female, Biomarkers, Tumor genetics, Biomarkers, Tumor blood, Breast Neoplasms genetics, Breast Neoplasms therapy, Circulating Tumor DNA blood, Circulating Tumor DNA genetics
- Published
- 2024
- Full Text
- View/download PDF
34. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
- Author
-
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, and Bellmunt J
- Subjects
- Humans, Adjuvants, Immunologic, Platinum, Retrospective Studies, Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
- Abstract
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy., Patients and Methods: Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors., Results: In total, 836 patients were included: 544 patients (65%) received pembrolizumab after progression to first-line platinum-based chemotherapy in the metastatic setting (cohort A) and 292 (35%) after recurring within < 12 months since the completion of adjuvant or neoadjuvant chemotherapy (cohort B). The median follow-up time was 15.3 months. The median OS and the ORR were 10.5 months and 31% in the overall study population, 9.1 months and 29% in cohort A and 14.6 months and 37% in cohort B. At multivariate analysis, ECOG-PS ≥ 2, bone metastases, liver metastases and pembrolizumab setting (cohort A vs B) proved to be significantly associated with worst OS and PFS. Stratified by the presence of 0, 1-2 or 3-4 prognostic factors, the median OS was 29.4, 12.5 and 4.1 months (p < 0.001), while the median PFS was 12.2, 6.4 and 2.8 months, respectively (p < 0.001)., Conclusions: Our study confirms that pembrolizumab is effective in the advanced UC real-world context, showing outcome differences between patients recurred or progressed after platinum-based chemotherapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
- Author
-
Santoni M, Massari F, Takeshita H, Tapia JC, Dionese M, Pichler R, Rizzo M, Lam ET, Grande E, Kemp R, Molina-Cerrillo J, Calabrò F, Tural D, Küronya Z, Kucharz J, Fiala O, Seront E, Kopp RM, Abahssain H, Kopecky J, Martignetti A, Kanesvaran R, Zakopoulou R, Ansari J, Landmesser J, Mollica V, Porta C, Bellmunt J, Salah S, and Santini D
- Subjects
- Humans, Retrospective Studies, Neoplasm Recurrence, Local, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell radiotherapy, Urinary Bladder Neoplasms pathology, Antineoplastic Agents therapeutic use, Bone Neoplasms drug therapy, Bone Neoplasms radiotherapy, Liver Neoplasms drug therapy
- Abstract
The ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC) patients with bone metastases (BM). Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were reviewed from60 institutions in 20 countries. Patients were assessed for Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 881 patients were included; of them, 263 (30%) presented BM. Median follow-up time was 22.7 months. Patients with BM showed both shorter median OS (5.9 months vs 13.1 months, p < 0.001) and PFS (3.5 months, vs 7.3 months, p < 0.001) compared to patients without BM. Patients who received bone targeted agents (BTAs) showed a significantly longer median OS (8.5 months vs 4.6 months, p = 0.003) and PFS (6.1 months vs 3.2 months, p = 0.003), while no survival benefits were observed among patients who received radiation therapy for BM during pembrolizumab treatment compared to those who did not. In multivariate analysis, performance status, concomitant liver metastases, and the lack of use of BTAs were significantly associated with worse OS and PFS. Bone involvement in UC patients treated with pembrolizumab predicts inferior survival. Poor performance status and liver metastases may further worsen outcomes, while the use of BTAs is associated with improved outcomes., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
36. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
- Author
-
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bisonni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, and Santoni M
- Subjects
- Humans, Proton Pump Inhibitors, Retrospective Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Metformin therapeutic use, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
- Abstract
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab., Methods: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model., Results: A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival., Conclusions: Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
37. CRS and HIPEC: Best model of antifragility in surgical oncology.
- Author
-
Souadka A, Essangri H, El Bahaoui N, Ghannam A, El Ahmadi B, Benkabbou A, Majbar MA, El Khannoussi B, Abahssain H, Mohsine R, and Belkhadir ZH
- Subjects
- Combined Modality Therapy, Cytoreduction Surgical Procedures, Humans, Hyperthermic Intraperitoneal Chemotherapy, Retrospective Studies, Hyperthermia, Induced, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms surgery, Surgical Oncology
- Published
- 2022
- Full Text
- View/download PDF
38. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival.
- Author
-
Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, Myint ZW, Zabalza IO, Battelli N, and Grande E
- Subjects
- Apoptosis, Cell Proliferation, Humans, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell pathology, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology
- Abstract
Statins are commonly prescribed to reduce plasma cholesterol levels and risk of cardiovascular events and mortality. Statin exposure may have cancer-preventive properties in some solid tumors, including Renal Cell Carcinoma (RCC). Emerging evidences show that statins can inhibit RCC cell growth by inducing cell cycle arrest and apoptosis in a dose- and time-dependent manner. In addition, statins inhibit the phosphorylation of AKT, mammalian target of rapamycin (mTOR), and ERK leading to reduced motility of RCC cells. Interestingly, the potential impact of concomitant statin intake has been recently evaluated in RCC patients treated by targeted therapy or immunotherapy. In this review, we illustrate the most recent data on the preclinical activity of statins in Renal Cell Carcinoma models and discuss the impact of their use on the prevention and survival of patients affected by this tumor., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
39. Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer.
- Author
-
Lemine Sow M, El Yacoubi H, Moukafih B, Balde S, Akimana G, Najem S, El Khoyaali S, Abahssain H, Chaibi A, Zeb Khan S, Trapani D, Benzekri A, Ghaouti M, Gamra L, Mestari A, Kettani F, Rahali Y, Mrabti H, Elghissassi I, and Errihani H
- Subjects
- Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung pathology, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, ErbB Receptors genetics, Female, Follow-Up Studies, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Morocco epidemiology, Prognosis, Retrospective Studies, Adenocarcinoma of Lung epidemiology, Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung epidemiology, Lung Neoplasms epidemiology, Mutation Rate
- Abstract
Background: Mutations in the epidermal growth factor receptor ( EGFR ) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology. The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion reported in Asian populations than Caucasian populations. There is a lack of data on these mutations in north Africa., Methods: Tumor specimens from Moroccan patients with NSCLC were collected from five pathology laboratories between November 2010 and December 2017 to determine frequency and types of EGFR mutations. Tumors were tested in a reference center for EGFR by polymerase chain reaction and sequencing of exons 18, 19, 20, and 21., Results: A total of 334 patients were enrolled: 242 (72.5%) males and 92 females (27.5%). A total of 56.9% had a history of smoking. EGFR testing of the 334 lung adenocarcinoma samples demonstrated a wild-type EGFR in 261 (78.1%) and mutated EGFR in 73 (21.9%). Mutations were mainly detected in the exon 19 deletion (65.8%), followed by exon 21 L858 (17.8%) and other exon 21 codon mutations (5.5%) and exon 18 (6.8%), whereas primary mutations of exon 20 were less frequent (4.1%). In patients with advanced NSCLC, the detection of EGFR mutation was independently associated with sex (41.3% female vs 14.5% male; p < 0.001) and smoking status (34.8% nonsmokers vs 12.9% active smokers; p < 0.001). The mean age was significantly different between the two groups ( p = 0.041)., Conclusion: Our findings confirm the genetic heterogeneity of NSCLC worldwide, reporting frequency of EGFR mutations in Moroccan patients with NSCLC between those of Asian and Caucasian populations.
- Published
- 2021
- Full Text
- View/download PDF
40. Impact of clinical pharmacy services in a hematology/oncology ward in Morocco.
- Author
-
Moukafih B, Abahssain H, Mrabti H, Errihani H, Rahali Y, Taoufik J, and Chaibi A
- Subjects
- Drug Interactions, Drug Monitoring, Female, Hematology, Humans, Male, Medical Oncology, Medication Errors statistics & numerical data, Middle Aged, Morocco, Pharmacy Service, Hospital, Prospective Studies, Drug Prescriptions standards, Medication Errors prevention & control, Neoplasms drug therapy, Pharmacists, Professional Role
- Abstract
Background: Clinical pharmacists are contributing to safe medication use by providing comprehensive management to patients and medical staff. The aim of this study is to document and evaluate the role of clinical pharmacy services in oncology department., Patients and Methods: A prospective, descriptive, observational study was carried out from July 2018 through June 2019 at the Department of Medical Oncology at the National Institute of Oncology, Morocco. Medication reviews concerning hospitalized adult cancer patients were performed every day by the clinical pharmacist assigned to the department., Results: A total of 3542 prescriptions of 526 adult cancer patients were analyzed. The pharmacist identified 450 drug-related problems (12.7% of the prescriptions) primarily related to the analgesics (31.5%). Medication problems included mostly untreated indications (31.3%), overdosing (17.1%), drug-drug interactions (12.4%), underdosing (11.1%), administration omissions (6.7%), drug not indicated (6.0%), and contraindication (5.3%). Interventions ( n = 450) led to drug additions (30.7%), drug dosing adjustments (27.1%), treatment discontinuations (20.0%), recall of the treatment (6.2%), replacement of a drug with another one (5.1%), administration optimization (4.0%), therapeutic drug monitoring (3.1%), alternate routes of administration (2.5%), and extension of treatment duration (1.3%). Most (98%) of the interventions were accepted and implemented by the medical staff-172 (38.2%) having a significant clinical impact on the patient, 88 (19.6%) as having a very significant clinical impact, and 71(15.8%) as having a potential vital impact., Conclusion: This work highlights the positive clinical relevance of pharmacists' interventions in oncology and the importance of medicopharmaceutical collaboration to prevent medication error.
- Published
- 2021
- Full Text
- View/download PDF
41. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
- Author
-
Abahssain H, Moukafih B, Essangri H, Mrabti H, Meddah B, Guessous F, Fadhil FZ, Souadka A, and Errihani H
- Subjects
- Aged, Brain diagnostic imaging, Brain Diseases diagnostic imaging, Creatinine blood, Drug-Related Side Effects and Adverse Reactions drug therapy, Female, Humans, Infusions, Intravenous, Male, Methylene Blue adverse effects, Middle Aged, Morocco, Retrospective Studies, Tomography, X-Ray Computed, Antineoplastic Agents, Alkylating adverse effects, Brain Diseases chemically induced, Brain Diseases drug therapy, Ifosfamide adverse effects, Methylene Blue therapeutic use
- Abstract
Background: Ifosfamide-induced encephalopathy (IIE) is a rare and serious adverse reaction. Thus far, no standard medication has been documentedto be efficient in the reversal of IIE, and while ifosfamide infusion interruption and hydration are recommended, methylene blue (MB) administration remains controversial., Methods: We retrospectively reviewed medical records to assess cases with IIE after ifosfamide infusion. We included all patients having received an ifosfamide infusion during their hospitalization in the medical oncology unit of the National Institute of Oncology in Rabat, Morocco, between September 2016 and September 2017. We subsequently conducted a literature review to determine the role of MB in IIE by searching PubMed using the terms "Methylene Blue" and "Ifosfamide"., Results: A total of 88 patients received ifosfamide, and four patients had IIE. Ifosfamide infusion was stopped immediately after the IIE occurrence, and patients underwent renal function correction with hydration. All patients received MB infusion, and three patients had an improvement of their neurological status. As regards the literature review, 34 articles were reviewed and 16 items were included in the review. Overall, 38 (65.5%) patients received MB infusion and 28 (75.6%) patients responded favorably to the treatment., Conclusions: Methylene blue can be used as a treatment for IIE owing to the severity of the IIE as well as absence of standard medication. Nonetheless, side effects such as serotonergic syndrome should be investigated. More broadly, prospective studies and controlled trials are needed to explore the contribution of MB in IIE management and encourage its use.
- Published
- 2021
- Full Text
- View/download PDF
42. Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologists.
- Author
-
Mrabti H, Berrada N, Raiss G, Ettahri H, Abahssain H, Bourhafour M, Sahraoui S, and Errihani H
- Subjects
- Betacoronavirus, COVID-19, Coronavirus Infections epidemiology, Delivery of Health Care, Developing Countries, Humans, Medical Oncology organization & administration, Morocco epidemiology, Neoplasms diagnosis, Pneumonia, Viral epidemiology, Practice Guidelines as Topic, SARS-CoV-2, Coronavirus Infections prevention & control, Medical Oncology standards, Neoplasms therapy, Oncologists standards, Pandemics prevention & control, Pneumonia, Viral prevention & control
- Abstract
Management of cancer patients during the COVID-19 pandemic is a worldwide challenge - in particular in developing countries where the risk of saturation of health facilities and intensive care beds must be minimized. The first case of COVID-19 was declared in Morocco on 2 March 2020, after which a panel of Moroccan experts, consisting of medical oncologists from universities and regional and private oncology centers, was promptly assembled to conduct a group reflection on cancer patient's management. The main objective is to protect the immunocompromised population from the risk of COVID-19, while maintaining an adequate management of cancer, which can quickly compromise their prognosis. Recommendations are provided according to each clinical situation: patients undergoing treatment, new cases, hospitalized patients, palliative care and surveillance.
- Published
- 2020
- Full Text
- View/download PDF
43. Vinorelbine and carboplatin-induced black tongue: A case report.
- Author
-
Sow ML, Moukafih B, Balde S, Elkhoyaali S, Chaibi A, Abahssain H, Mrabti H, and Errihani H
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin adverse effects, Humans, Treatment Outcome, Vinorelbine adverse effects, Lung Neoplasms drug therapy, Tongue, Hairy
- Published
- 2020
- Full Text
- View/download PDF
44. Quality of life of early stage colorectal cancer patients in Morocco.
- Author
-
Mrabti H, Amziren M, ElGhissassi I, Bensouda Y, Berrada N, Abahssain H, Boutayeb S, El Fakir S, Nejjari C, Benider A, Mellas N, El Mesbahi O, Bennani M, Bekkali R, Zidouh A, and Errihani H
- Subjects
- Adult, Aged, Aged, 80 and over, Anorexia psychology, Colorectal Neoplasms therapy, Early Detection of Cancer, Emotions, Fatigue psychology, Female, Health Status, Humans, Male, Middle Aged, Morocco, Neoplasm Staging, Prospective Studies, Sex Factors, Socioeconomic Factors, Surveys and Questionnaires, Young Adult, Colorectal Neoplasms pathology, Colorectal Neoplasms psychology, Quality of Life
- Abstract
Background: A multicentre cohort study was held in Morocco, designed to evaluate the quality of life of cancer patients. The aim of this paper is to report the assessment of the quality of life of early colorectal cancer patients, before and after cancer treatment, to identify other factors which are related to this quality of life., Methods: We used the third version of the QLQ-C30 questionnaire of the European organization for Research and treatment of Cancer (EORTC) after a transcultural validation. The Data collection was done at inclusion and then every twelve weeks to achieve one year of follow up., Results: Overall 294 patients presented with early colorectal cancer, the median age was 56 years (range: 21-88). The male-female sex ratio was 1.17. At inclusion, the global health status was the most affected functional dimension. For symptoms: financial difficulties and fatigue scores were the highest ones. Emotional and social functions were significantly worse in rectal cancer. Most symptoms were more present in rectal cancer. At inclusion, global health status score was significantly worse in stage III. Anorexia was significantly more important among colorectal female patients. For Patients over 70 years-old, the difference was statistically significant for the physical function item which was lower. Overall, Functional dimensions scores were improved after chemotherapy. The symptoms scores did not differ significantly for patients treated by radiotherapy, between inclusion and at one year., Conclusion: Our EORTC QLQ C30 scores are overall comparable to the reference values. Neither chemotherapy, nor radiotherapy worsened the quality of life at one year.
- Published
- 2016
- Full Text
- View/download PDF
45. Breast and splenic metastases of squamous cell carcinoma from the uterine cervix: a case report.
- Author
-
Aitelhaj M, Khoyaali SL, Boukir A, Elkabous M, Abahssain H, Mrabti H, El Khannoussi B, and Errihani H
- Subjects
- Fatal Outcome, Female, Humans, Middle Aged, Neoplasm Staging, Uterine Cervical Neoplasms therapy, Breast Neoplasms secondary, Carcinoma, Squamous Cell secondary, Splenic Neoplasms secondary, Uterine Cervical Neoplasms pathology
- Abstract
Introduction: Metastases to the breast from extramammary malignancies are infrequent, the most common primary sites are malignant melanoma, leukemia, lymphoma, and cancer of the lung, stomach, prostate and ovary. The cervical origin is exceptional. Splenic metastasis from squamous cell carcinoma of the cervix is also rare. To the best of our knowledge, only three cases of isolated splenic metastasis have been reported in the literature., Case Presentation: We describe the case of a 55-year-old North African woman who presented with a nodule in her left breast eight months after treatment for stage IIB squamous cell uterine cervical carcinoma. The excisional biopsy with histological study demonstrated a poorly differentiated squamous cell carcinoma. A computed tomography scan revealed a splenic secondary location., Conclusions: We report here a case of two unusual metastatic sites of uterine cervical carcinoma, the breast and spleen. It is the first case of this association without widespread disease.
- Published
- 2014
- Full Text
- View/download PDF
46. [Gastrointestinal stromal tumors].
- Author
-
Sekkate S, Kairouani M, Abahssain H, Serji B, Boutayeb S, Mrabti H, and Errihani H
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Diagnosis, Differential, Digestive System Surgical Procedures, Humans, Molecular Targeted Therapy methods, Prognosis, Gastrointestinal Stromal Tumors diagnosis, Gastrointestinal Stromal Tumors epidemiology, Gastrointestinal Stromal Tumors etiology, Gastrointestinal Stromal Tumors therapy
- Abstract
Gastrointestinal stromal tumors (GIST) are the most common sarcomas of the gastrointestinal tract. They affect all segments of the digestive tract. They develop from the interstitial cells of Cajal. Mutations in the Kit gene is present in 86% of cases and in PDGFR gene in 15% of cases. The marker CD 117 is present in 95% of cases. Surgery is the standard treatment in localized forms. The tyrosine kinase inhibitor, imatinib is standard in first-line metastatic gastrointestinal stromal tumors, as well as adjuvant treatment after surgery. Sunitinib is the standard in second line., (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
47. A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy.
- Author
-
Kairouani M, Sekkate S, Ismaili N, Abahssain H, and Errihani H
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Edema etiology, Humans, Intensive Care Units, Lung Neoplasms secondary, Male, Mycosis Fungoides drug therapy, Neoplasm Staging, Nephrotic Syndrome diagnosis, Prednisone therapeutic use, Skin Neoplasms drug therapy, Tomography, X-Ray Computed, Treatment Outcome, Vincristine therapeutic use, Whole Body Imaging, Mycosis Fungoides diagnosis, Nephrotic Syndrome etiology, Skin Neoplasms diagnosis
- Abstract
The occurrence of the nephrotic syndrome during mycosis fungoide is very unusual. We report a rare case of mycosis fungoide revealed by hydrops related to nephrotic syndrom in a 37-year old male patient. He has been admitted to intensive care unit because of a breathing distress and a hydrophobs. Whole body computed tomography scan revealed bilateral axillary, cervical lymph nodes, tumoral infiltration of the subcutaneous tissue in the cervicothoracic and abdominal regions, multiples bilateral pulmonary metastasis, bilateral pleural effusion, and abdominal effusion; the kidneys were normal. The patient was staged IVb (T3N3M1). He was treated with CHOP (cyclophosphamide, Doxorubicin, Vincristin and prednisone). Evolution after eight cycles of chemotherapy was spectacular. The development of nephrotic syndrom secondary to mycosis fungoide is rare. It requires a multidisciplinary approach with nephrologists and oncologists.
- Published
- 2012
48. Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.
- Author
-
Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M, and Thomas X
- Subjects
- Adult, Aged, Anthracyclines administration & dosage, Cytarabine administration & dosage, Female, Follow-Up Studies, Humans, Immunophenotyping, Karyotyping, Leukemia, Myeloid, Acute drug therapy, Male, Middle Aged, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Differentiation, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology
- Abstract
Data from 42 adult patients with newly diagnosed minimally differentiated (M0) acute myeloid leukemia (AML) were reported. Clinical and biological characteristics at diagnosis were heterogenous. All patients received induction chemotherapy combining an anthracycline with cytarabine. Complete remission (CR) was achieved in 22 cases (52%). Most patients received continuation chemotherapy. Median disease-free survival (DFS) was 13.6 months with a 2-year survival rate of 28%. As post-remission therapy, 7 patients could be allografted and showed an encouraging outcome. Overall, 14 patients have relapsed (63%) after a median time of 10.2 months. Median overall survival (OS) was 20.5 months with a 5-year survival rate of 18%. This retrospective analysis points to a somewhat heterogenous group of AML in terms of biological features and outcome, and warrants a larger multicenter study with study in molecular biology to clarify treatment effects further., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
49. [Primary malignant tumors of the small intestine: clinical and therapeutic aspects of 27 patients].
- Author
-
Abahssain H, Mokrim M, Lalya I, M'rabti H, and Errihani H
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Intestinal Neoplasms diagnosis, Intestinal Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Intestinal Neoplasms therapy, Intestine, Small pathology
- Published
- 2011
50. [Chemotherapy in gallbladder carcinoma].
- Author
-
Abahssain H, Afchain P, Melas N, Ismaili N, Rahali R, Rabti HM, and Errihani H
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Bile Duct Neoplasms drug therapy, Bile Duct Neoplasms mortality, Bile Duct Neoplasms pathology, Bile Duct Neoplasms surgery, Capecitabine, Cisplatin administration & dosage, Cisplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Fluorouracil administration & dosage, Fluorouracil adverse effects, Fluorouracil analogs & derivatives, Gallbladder Neoplasms mortality, Gallbladder Neoplasms pathology, Gallbladder Neoplasms surgery, Humans, Leucovorin administration & dosage, Leucovorin adverse effects, Mitomycin administration & dosage, Mitomycin adverse effects, Neoplasm Invasiveness, Neoplasm Staging, Randomized Controlled Trials as Topic, Survival Rate, Treatment Outcome, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gallbladder Neoplasms drug therapy
- Abstract
Gallbladder cancer is an aggressive tumor. Its incidence varies according to geography. Surgery is the standard treatment for localized stage but there is no standard treatment in metastatic or locally advanced disease. Because of the rarity of bile tract cancer (BTC) and gallblader carcinoma (GBC), most studies have grouped all BTC and GBC together, and there are very few GBC-specific studies. In addition, there is a paucity of randomized controlled studies in this disease with small numbers of patients and inclusion bias. One randomized trial ABC-02 was well conducted and showed a survival benefit in favor of gemcitabine (GEM)+cisplatin (CDDP), which can be regarded as the standard in locally advanced BTC. Adjuvant therapy after surgical resection is not validated. Understanding the molecular mechanisms of carcinogenesis of GBC has opened the way for the use of targeted therapies. This new treatment would improve survival and quality of life of our patients., (Copyright © 2010 Elsevier Masson SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.